Usmani, S., Mielnik, M., Alonso, A. A., Abdallah, A., Garg, M., Janowski, W., Koh, Y., Min, C., Ocio, E., Quach, H., Ramasamy, K., Oriol, A., Rodriguez-Otero, P., Sanchez, R. G., Sandhu, I., Weisel, K., Brawley, C., Murillo, M., Carreño, F., Egger, J., Kaisermann, M., Hus, M. (2025). Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study. Blood. https://doi.org/10.1182/blood-2025-5840